Company / Current Liabilities per Share
Dianthus Therapeutics, Inc. /DE/ Current Liabilities per Share History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities per Share
$0.99
FY2025
5-year range
$0.20 / $9.41
FY2021-FY2025
Trend
-20.7%
vs FY2024
Sector context
#115 of 210
Health Care
What the data says
At $0.99, Dianthus Therapeutics, Inc. /DE/'s current liabilities per share ranks #96 of 210 in the Health Care sector. Current Liabilities per Share has declined for 3 consecutive years, from $9.41 in FY2022 to $0.99 in FY2025.
Based on SEC 10-K filings.
0.99 in FY2025 with a 5-year CAGR of +30.6%.
Improved from $1.87 to $0.99 over the past 2 years.
Health Care sector context is included.
Current Liabilities per Share over time
Growth rates
- 3-Year CAGR
- -52.8%
- 5-Year CAGR
- +30.6%
- 10-Year CAGR
- -
Sector benchmark
#96 of 210 in Health CareTop 45% of 210This company $0.99 Sector average $15.78
▼
-93.7% below sector average
Key checks
Key Insights
- Dianthus Therapeutics, Inc. /DE/'s current liabilities per share has declined for 3 consecutive years.
- In FY2025, current liabilities per share decreased 20.7% year-over-year.
- Ranks #115 out of 210 companies in the Health Care sector.
- Peak current liabilities per share was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.46 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current Liabilities per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.99 | -20.7% |
| FY2024 | $1.25 | -33.4% |
| FY2023 | $1.87 | -80.1% |
| FY2022 | $9.41 | +4659.0% |
| FY2021 | $0.20 | -24.0% |
| FY2020 | $0.26 | -38.6% |
| FY2019 | $0.42 | -90.4% |
| FY2018 | $4.43 | +98.7% |
| FY2017 | $2.23 | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026